Related Experiment Video

Updated: Aug 21, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial)

Hans Rickli1, Simon Steiner, Karin Müller

  • 1Division of Cardiology, St. Gallen, Switzerland.

European Journal of Heart Failure
|November 16, 2004
PubMed

Insights

Carvedilol is a safe and well-tolerated beta blocker for chronic heart failure (CHF) patients. General practitioners can effectively manage carvedilol treatment, showing significant improvements in heart failure symptoms and quality of life.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Beta blockers are essential for managing chronic heart failure (CHF).
  • Assessing the safety and tolerability of carvedilol in CHF patients is crucial for effective treatment.
  • Standard therapy for CHF often includes ACE-inhibitors and diuretics.

Purpose of the Study:

  • To evaluate the safety and tolerability of carvedilol in patients with chronic heart failure.
  • To assess the efficacy of carvedilol in improving clinical outcomes in CHF patients.
  • To determine the feasibility of carvedilol initiation and management by general practitioners.

Main Methods:

  • 151 CHF patients were enrolled by 66 general practitioners under cardiologist supervision.
  • Carvedilol treatment was initiated at 3.125 mg twice daily, with gradual uptitration to 2x25 mg daily over 2-week intervals.
  • The study involved a mean follow-up period of 12 weeks.

Main Results:

  • 96% of patients completed the study; only 4% were lost to follow-up.
  • 41% experienced minor adverse events, and 6% had serious adverse events.
  • Significant improvements were observed in NYHA class (2.2 to 1.8), heart rate (78 to 69 bpm), blood pressure, and quality of life (Minnesota Living with Heart Failure score reduction from 1.28 to 0.88).

Conclusions:

  • Carvedilol demonstrates good tolerability and safety in CHF patients managed by general practitioners.
  • Serious adverse events and hospitalizations associated with carvedilol use are infrequent.
  • Carvedilol can be safely initiated and managed in primary care settings for CHF treatment.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...